These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24414704)

  • 1. Age-related epigenetic drift in the pathogenesis of MDS and AML.
    Maegawa S; Gough SM; Watanabe-Okochi N; Lu Y; Zhang N; Castoro RJ; Estecio MR; Jelinek J; Liang S; Kitamura T; Aplan PD; Issa JP
    Genome Res; 2014 Apr; 24(4):580-91. PubMed ID: 24414704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
    Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
    Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
    Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
    Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
    Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
    Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic changes in therapy-related MDS/AML.
    Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
    Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes.
    Zhou JD; Zhang TJ; Xu ZJ; Deng ZQ; Gu Y; Ma JC; Wen XM; Leng JY; Lin J; Chen SN; Qian J
    Cell Death Dis; 2020 Nov; 11(11):997. PubMed ID: 33219204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular bases of myelodysplastic syndromes: lessons from animal models.
    Komeno Y; Kitaura J; Kitamura T
    J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.
    Slape C; Lin YW; Hartung H; Zhang Z; Wolff L; Aplan PD
    J Natl Cancer Inst Monogr; 2008; (39):64-8. PubMed ID: 18648006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
    Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG
    Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia.
    Roux B; Picou F; Debeissat C; Koubi M; Gallay N; Hirsch P; Ravalet N; Béné MC; Maigre M; Hunault M; Mosser J; Etcheverry A; Gyan E; Delhommeau F; Domenech J; Herault O
    Cancer Gene Ther; 2022 Aug; 29(8-9):1263-1275. PubMed ID: 35194200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
    Benetatos L; Dasoula A; Hatzimichael E; Syed N; Voukelatou M; Dranitsaris G; Bourantas KL; Crook T
    Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.
    Sashida G; Harada H; Matsui H; Oshima M; Yui M; Harada Y; Tanaka S; Mochizuki-Kashio M; Wang C; Saraya A; Muto T; Hayashi Y; Suzuki K; Nakajima H; Inaba T; Koseki H; Huang G; Kitamura T; Iwama A
    Nat Commun; 2014 Jun; 5():4177. PubMed ID: 24953053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
    Babushok DV; Bessler M
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
    Harada H; Harada Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.